Patent · US Active

Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

US7867775B2 · kind B2 · utility

15Cited by

1References

5Claims

0Family size

Assignee

Biodesix, Inc. · US

Inventors

Heinrich Röder · Steamboat Springs, US
Maxim Tsypin · Steamboat Springs, US
Julia Grigorieva · Steamboat Springs, US

Key dates

Filing date	Jan 20, 2009
Grant date	Jan 11, 2011
Priority date	—
Expiry date	Jan 20, 2029

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10T436/24
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a head and neck squamous cell carcinoma (HNSCC) patient is likely to benefit from a drug targeting an epidermal growth factor receptor pathway, including small molecule epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and monoclonal antibody EGFR inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.